



African Journal of Urology

Official journal of the Pan African Urological Surgeon's Association
web page of the journal

www.ees.elsevier.com/afju
www.sciencedirect.com



Prostate diseases

Original article

Comparison of the pre-treatment testosterone levels in benign prostatic hyperplasia and prostate cancer patients



D.E. Orakwe*, K.H. Tijani, E.A. Jeje, M.A. Ogunjimi, R.W. Ojewola

Department of Surgery, Lagos University Teaching Hospital, Idi-Araba, Lagos State, Nigeria

Received 25 February 2016; received in revised form 15 March 2016; accepted 29 March 2016

Available online 26 January 2017

KEYWORDS

Serum testosterone;
Prostate cancer;
Benign prostatic hyperplasia;
Serum prostate specific antigen

Abstract

Objectives: To compare serum testosterone and prostate specific antigen (PSA) levels of patients diagnosed of prostate cancer to those with benign prostatic hyperplasia (BPH).

Subjects and methods: One hundred and thirteen male patients with or without LUTS who had indication(s) for prostate biopsies were recruited. Blood samples were analysed for serum testosterone and serum PSA. Prostate sizes were measured and PSA densities calculated before trans-rectal prostate biopsies were performed.

Results: On histology of prostate biopsy specimens, 54 patients (47.8%) had prostate adenocarcinoma while 59 patients (52.2%) had BPH. Serum testosterone levels were lower in the prostate cancer group (23.09 ± 2.31 nmol/L versus 24.37 ± 1.94 nmol/L in the BPH group) but this difference was not statistically significant ($p = 0.671$). Serum testosterone also did not differ significantly with Gleason grade and Gleason score in patients with prostate cancer.

Serum PSA and PSA density (PSAD) values were significantly higher in men with prostate cancer, and also in prostate cancer patients with high grade disease.

Conclusion: Serum testosterone levels of patients with prostate cancer did not significantly differ from those of patients with BPH and were not related to grade in prostate cancer patients.

© 2016 Pan African Urological Surgeons' Association. Production and hosting by Elsevier B.V. All rights reserved.

* Corresponding author.

E-mail address: dubyorakwe@yahoo.co.uk (D.E. Orakwe).

Peer review under responsibility of Pan African Urological Surgeons' Association.

<http://dx.doi.org/10.1016/j.afju.2016.03.004>

1110-5704/© 2016 Pan African Urological Surgeons' Association. Production and hosting by Elsevier B.V. All rights reserved.

Introduction

Prostate cancer is the second most frequently diagnosed cancer of men and the incidence varies by race/ethnicity, with African-Americans at highest risk in America [1]. In the African subregion, prostate cancer presents approximately a decade earlier than it does in western countries, however, the patients still present with advanced disease in over 70% of cases [2,3]. In these patients, the disease also tends to progress more rapidly and Gleason score tends to be higher [3]. Though the Nigerian nationwide incidence is yet to be directly evaluated [2], Nigerian men seem to be at also at high risk of prostate cancer like the African-Americans judging from data gleaned from the population-based and hospital based cancer registries which indicate that prostate cancer is the commonest malignant tumour among Nigerian men [4].

Though the search for novel (and more prostate cancer specific) tumour markers continues, serum PSA estimation remains an important tool for Prostate cancer detection [5]. Tissue and serum level of androgens in those with or without prostate cancer have over the years been part of the focus of the search for better tumour markers for prostate cancer. Serum testosterone and other androgens are considered important in the growth and development of the prostate as well as in the pathogenesis of prostate cancer [6]. However, over the years, reports have been conflicting with no clear consensus and the importance of its determination for patient management in terms of diagnosis, prognosis and staging has been poorly understood [6,7]. Researchers have at different times reported low serum testosterone levels [8–10] and high serum testosterone levels [11,12] in patients with prostate cancer when compared to those without prostate cancer. Some found no significant differences in serum testosterone levels on comparison [13–16]. A review of 25 studies comparing testosterone levels in a total of 2767 controls and 1481 patients with prostate cancer reported that the mean testosterone levels at diagnosis were the same in both groups in 15 studies (60%), higher in prostate cancer patients in four (16%) and lower in six (24%) [6].

After an online PUBMED search, a study conducted in our institution by Osegebe and Ogunlewe [17] (published in 1988) was the only similar study found. They measured and compared serum testosterone levels in prostate cancer, benign prostatic hyperplasia (BPH) and normal patients and found that serum testosterone was significantly lower in those with prostate cancer.

There is a paucity of studies of such research in the predominantly black sub-Saharan Africa, therefore, we also sought to compare pre-treatment serum testosterone levels in benign prostatic hyperplasia (BPH) and prostate cancer patients presenting in our centre in Nigeria.

Subjects and methods

This study was a prospective comparative study conducted at our institution over 16 months (March 2013–June 2014). Approval was obtained from the Research and Ethics Committee of the Lagos University Teaching Hospital before commencement of the study. Male patients above 40 years with or without symptoms of prostatic disease who had indications for prostate biopsy were enrolled into the study from the Urology Outpatient Clinics and wards after informed consent had been obtained. The indications for prostate biopsy were features suggestive of prostatic malignancy on digital

rectal examination and/or serum PSA elevated above the level expected for age. The age-specific levels used were 0–2.5 ng/ml for men aged 40–49 years, 0–3.5 ng/ml for those aged 50–59 years, 0–4.5 ng/ml for those aged 60–69 years and 0–6.5 ng/ml for those aged 70–79 years. Patients excluded from the study were those on 5- α reductase inhibitors, those that already had radiotherapy as treatment before presentation, those already on androgen deprivation therapy and men on androgen supplementation for hypogonadism.

Other clinical data collected included the bio-data (age, sex, occupation, marital status), presenting complaints, duration of illness/problems, history presenting complaints including lower urinary tract symptoms and haematuria, any history suggestive of expected complications (like acute urinary retention, renal failure), history suggestive of prostatic malignancy (and metastases) and history of co-morbid conditions (e.g. diabetes mellitus, hepatic diseases, hypertension). Physical examination findings were also noted.

Fasting blood samples were collected between 7 am and 10 am. Serum was stored at -80°C and were subsequently analysed by quantitative determination for serum prostate specific antigen and testosterone using enzyme immunoassay kits made by Rapid labs (UK). Analytical sensitivity for the total PSA assay kit was 0.3 ng/ml while that of the total testosterone kit was 0.2 nmol/l. The analysis of the serum samples were done by 2 chemical pathologists working together who were blinded to the histology results or clinical status of the patients.

The sizes of the prostates were measured using a 3.5 MHz trans-abdominal ultrasound probe and the volumes were expressed in cm^3 . Subsequently, trans-rectal prostate biopsies (minimum of 10 cores – sextant + 4 extended cores) were done for all patients with histology of the prostate biopsy specimens which formed the basis for categorising the patients into 2 groups – prostate cancer group and benign prostatic hyperplasia (BPH) group. The Gleason grades and scores were also recorded for the prostate adenocarcinoma specimens on histology. The histology of the specimens was done by a pathologist specialised in prostatic diseases who was blinded to the results of the serum PSA and testosterone.

The data were analysed using the Statistical Package of Social Sciences (SPSS) version 16.0. The Student's *t*-test was used for test of significance with confidence interval of 95%. A *p*-value of <0.05 was considered statistically significant.

Results

A total of 113 patients were recruited and on histology of the prostate biopsy specimens, 54 men (47.8%) had prostate cancer (prostate cancer group) while 59 men (52.2%) had benign prostatic hyperplasia (BPH group). The overall mean age was 67.9 ± 7.8 years (range 47–85 years) while the mean ages were 68.9 ± 7.9 years and 66.9 ± 7.6 years in the prostate cancer and BPH groups respectively. Patients in their seventh and eighth decades of life cumulatively accounted for 75.1% of all patients.

Overall, the mean serum PSA was 30.23 ± 26.41 ng/ml (range 0.02–88.36 ng/ml) while the overall mean serum testosterone was 23.8 ± 15.9 nmol/L (range 1.25–95.05 nmol/L). Within the individual groups, 46 (75.93%) of patients in BPH group had serum PSA

Download English Version:

<https://daneshyari.com/en/article/5729505>

Download Persian Version:

<https://daneshyari.com/article/5729505>

[Daneshyari.com](https://daneshyari.com)